Your cart is currently empty!
Movfor (Molnupiravir) Capsule
Generic brands for Molnupiravir Capsule Available in India Brand Name Movfor Generic Name Molnupiravir Strength 200mg Manufacturer Hetero Healthcare Ltd
Description
Description
This page contains brief details about the drug molnupiravir, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Molnupiravir is an antiviral medication containing the active constituent Molnupiravir. It treats mild to moderate COVID-19 (Coronavirus disease) in people at risk for developing severe illness. COVID-19 is a highly infectious disease caused by the SARS-CoV-2 virus. Molnupiravir is not recommended for adolescents and children under the age of 18. This drug must be taken within five days of the onset of symptoms to be most effective. Molnupiravir could also provide an alternative treatment option for COVID-19 patients who cannot receive or do not respond well to existing treatments, such as monoclonal antibodies or remdesivir.
Mechanism of Action of Molnupiravir
The work of Molnupiravir is to reduce the severity of COVID-19 symptoms and prevent the virus from replicating and spreading within the body. This is accomplished by introducing errors into the genetic material of the virus, which can ultimately render it unable to reproduce and cause further harm.
Uses of Molnupiravir
Molnupiravir is an antiviral drug used to treat mild to moderate COVID-19 in high-risk adults.
Molnupiravir Dosage available
Take Molnupiravir in the dose and duration prescribed by your doctor. Swallow the medication whole with plenty of water. Do not chew or crush the capsules. This capsule can be taken with or without food. Do not skip or miss doses.
We can ship to :
News/Updates
References
- Merck Sharp & Dohme (UK) Limited, Electronic medicines compendium (emc), [ Revised on Nov 2021] [ Accessed on 9th May 2023], https://www.medicines.org.uk/emc/files/pil.13044.pdf
- Florian Kabinger et al; Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis; Nature Structural & Molecular Biology; [Published on 11/08/2021]; [Accessed on 9 May 2023]; https://www.nature.com/articles/s41594-021-00651-0
- William Fischer et al; Molnupiravir, an Oral Antiviral Treatment for COVID-19; medRxiv; [Published on 17/06/2021]; [Accessed on 9th May 2023], https://pubmed.ncbi.nlm.nih.gov/34159342/